Summary:
A phase IIB, randomized, double-blind, dose-ranging study to assess the efficacy and safety of MSTT1041A in patients with uncontrolled severe asthma.
Qualified Participants Must:
• Be between 18 and 75 years of age at time of signing informed consent
•
Have a Body mass index (BMI) of 18-35kg/m₂ and weight > 40kg at screening
•
Have documented physician-diagnosed asthma for at least 12 months prior study visit
•
Patients on ICS + LABA(Inhaled Corticosteroid + Long-Acting Beta Agonists) such as Pulmicort, QVAR, Flovent, Asmanex, etc. + Advair, Symbicort, Dulera, etc.
• Documented history of at least one asthma exacerbation within 12 months prior to screening while on daily ICS maintenance therapy
• Hospitalization or emergency department or urgent care visit requiring administration of asthma treatment
• If female of childbearing potential and committed to consistent and correct use of an acceptable method of birth control
Qualified Participants May Receive:
Can get compensated up to $1,900, free treatment and doctor consultations with 24hr emergency phone line;